Valcamp Dosage/Direction for Use

Dosage: General target population: A patient whose blood pressure is not adequately controlled on monotherapy may be switched to combination therapy with amlodipine + valsartan (Valcamp).
The recommended dose is one tablet per day (the 3 strengths are listed in Description). When clinically appropriate direct change from monotherapy to the fixed-dose combination may be considered.
For convenience, patients receiving valsartan and amlodipine from separate tablets may be switched to amlodipine + valsartan (Valcamp) containing the same component doses.
Amlodipine + valsartan (Valcamp) may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of amlodipine + valsartan (Valcamp) as initial therapy for hypertension should be based on an assessment of potential benefits and risks.
For initial therapy, the Usual starting dose is amlodipine + valsartan (Valcamp) 5/80 mg once daily. The dosage
can be increased after 1 to 2 weeks of therapy to a maximum of one 10/320 mg tablet once daily as needed to control blood pressure.
Amlodipine + valsartan (Valcamp) is not recommended as initial therapy in patients with intravascular volume depletion (see Precautions).
The maximum dose is 10/320 mg.
Both amlodipine and valsartan monotherapy can be taken with or without food.
It is recommended to take amlodipine + valsartan (Valcamp) with some water.
Special populations: Renal impairment: No dose adjustment is required for patients with mild to moderate renal impairment.
Hepatic impairment: Due to amlodipine and valsartan, caution should be exercised when administering amlodipine + valsartan (Valcamp) to patients with hepatic impairment or biliary obstructive disorders. Starting with the lowest available dose of amlodipine should be considered. The lowest strength of amlodipine + valsartan (Valcamp) contains 5 mg of amlodipine (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Pediatric patients (below 18 years): Amlodipine + valsartan (Valcamp) is not recommended for use in patients aged below 18 years due to a lack of data on safety and efficacy.
Geriatric patients (aged 65 years or above): Since both components of the combination are equally well tolerated when used at similar doses in elderly (aged 65 years or above) or younger patients, no dose adjustment of the starting dose is required. Starting with the lowest available dose of amlodipine should be considered. The lowest strength of amlodipine + valsartan (Valcamp) contains 5 mg of amlodipine (see Pharmacology: Pharmacokinetics under Actions).